IP Library Granted Patent US 9,872,845
Granted Patent B2
US 9,872,845 · App. 15/134,896 · Granted Jan 23, 2018

Methods of treating myeloma and lymphoma using compositions containing an ion pair of a lipoic acid derivative

Inventors: Robert G. L. Shorr (Edison, NJ); Robert J. Rodriguez (West Windsor, NJ); Rajinder Bhasin (Coram, NY)
Assignee: Rafael Pharmaceuticals, Inc.
A61K31/205A61K31/19A61K31/20A61K31/381A61K47/18A61K47/26A61K47/4803
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,872,845
App. No.
15/134,896
Granted
Jan 23, 2018
Kind
B2
Abstract

The invention provides a method of treating myeloma and lymphoma using a pharmaceutical composition containing a pharmaceutically acceptable diluent along with an ion pair formed by triethanolamine and a compound of Formula I:

Claims (24)

1. A method of treating a disease selected from the group consisting of myeloma and lymphoma, comprising administering to a patient in need thereof to treat the disease a therapeutically effective amount of a pharmaceutical formulation comprising:

(a) a compound of Formula I:

(b) triethanolamine; and

(c) a pharmaceutically acceptable diluent;

wherein the compound of Formula I and triethanolamine form an ion pair.

2. The method of claim 1 , wherein the disease is myeloma.

3. The method of claim 1 , wherein the disease is lymphoma.

4. The method of claim 1 , wherein the compound of Formula I and triethanolamine are present in a molar ratio ranging from about 20:1 to about 1:20.

5. The method of claim 2 , wherein the compound of Formula I and triethanolamine are present in a molar ratio ranging from about 20:1 to about 1:20.

6. The method of claim 3 , wherein the compound of Formula I and triethanolamine are present in a molar ratio ranging from about 20:1 to about 1:20.

7. The method of claim 1 , wherein the diluent is selected from the group consisting of saline, a sugar solution, an alcohol, dimethylformamide, dimethylsulfoxide, dimethylacetamide, and combinations thereof.

8. The method of claim 2 , wherein the diluent is selected from the group consisting of saline, a sugar solution, an alcohol, dimethylformamide, dimethylsulfoxide, dimethylacetamide, and combinations thereof.

9. The method of claim 3 , wherein the diluent is selected from the group consisting of saline, a sugar solution, an alcohol, dimethylformamide, dimethylsulfoxide, dimethylacetamide, and combinations thereof.

10. The method of claim 4 , wherein the diluent is selected from the group consisting of saline, a sugar solution, an alcohol, dimethylformamide, dimethylsulfoxide, dimethylacetamide, and combinations thereof.

11. The method of claim 5 , wherein the diluent is selected from the group consisting of saline, a sugar solution, an alcohol, dimethylformamide, dimethylsulfoxide, dimethylacetamide, and combinations thereof.

12. The method of claim 6 , wherein the diluent is selected from the group consisting of saline, a sugar solution, an alcohol, dimethylformamide, dimethylsulfoxide, dimethylacetamide, and combinations thereof.

13. The method of claim 1 , wherein the diluent is a dextrose solution.

14. The method of claim 2 , wherein the diluent is a dextrose solution.

15. The method of claim 3 , wherein the diluent is a dextrose solution.

16. The method of claim 4 , wherein the diluent is a dextrose solution.

17. The method of claim 5 , wherein the diluent is a dextrose solution.

18. The method of claim 6 , wherein the diluent is a dextrose solution.

19. The method of claim 17 , wherein the dextrose solution contains an amount of dextrose ranging from about 2.5% to about 10% by weight.

20. The method of claim 18 , wherein the dextrose solution contains an amount of dextrose ranging from about 2.5% to about 10% by weight.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2017
From: SHORR, ROBERT G.L.; RODRIGUEZ, ROBERT J.; BHASIN, RAJINDER
To: CORNERSTONE PHARMACEUTICALS, INC.
Reel/Frame 043357/0215 →
CHANGE OF NAME Recorded Aug 17, 2017
From: CORNERSTONE PHARMACEUTICALS, INC.
To: RAFAEL PHARMACEUTICALS, INC.
Reel/Frame 043582/0850 →
Continuity (5)
Continuation 14227148 · Mar 27, 2014
Continuation 13253503 · Oct 5, 2011
Continuation 12105100 · Apr 17, 2008
Provisional Application 60912605 · Apr 18, 2007
Related Publication 20170056355A1 · Mar 2, 2017